1Herranz R (2003) Cholecystokinin Antagonists: Pharmacological and Therapeutic Potential. MedResRev 23: 559.

2Mawe GM (1990) The role of cholecystokinin in ganglionic transmission in the guinea-pig gall-bladder. JPhysiol 439: 89.

3Jorpes E, Mutt V (1966) Cholecystokinin and Pancreozymin, one single Hormone? Acta Physiol Scand 66: 196.

4McDonald IM (2001) CCK2 receptor antagonists. Exp OpinTher Patents 11: 445.

5Bock MG, DiPardo RM,Mellin EC, et al. (1994) Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogues with selectivity and water solubility. J Med Chem 37: 722.

6Lattmann E, Arayarat P (2003) From CNS-drugs to anti-neoplastic agents: Cholecystokinin (CCK) antagonists as modern anti-cancer agents.KKU Science J 31: 178.

7Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11: 271.

8Rasmussen K, Czachura, JF, Stockton, ME, et al. (1993) Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol ExpTher 264: 480.

9Dourish CT, Rycroft,W, Iversen, SD (1989) Postponement of satiety by blockade of brain cholecystokinin-B receptors. Science 245: 1509.

10Chang R, Lotti V, Monaghan R, et al. (1985) A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 230: 177.

11Lattmann E, Billington DC, Poyner DR, et al. (2001) Synthesis and evaluation of Asperlicin analogues as non-peptidal Cholecystokinin-antagonists. Drug DesDiscov 17: 219.

12Evans BE, Rittle KE, Bock MG, et al. (1988) Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin-A antagonists. J Med Chem 31: 2235.

13Hahne W, Jensen R, Lemp G, et al.( 1981) Proglumide and benzotript: Members of a different class of cholecystokinin receptor antagonists. Proceedings of the National Academy of Sciences USA 78: 6304.

14Woodruff GN, Hughes J (1991) Cholecystokinin antagonists.Annu Rev Pharmacol Toxicol 31: 469.

15Hughes J, Woodruff GN (1992) Neuropeptides function and clinical applications. Arzneimittelforschung 42: 250.

16Meyer T, Caplin ME, Palmer DH, et al. (2010) A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. Eur J Cancer 46: 526.

17YekkiralaAS, Roberson DP, Bean BP, et al. (2017) Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov 16: 545.

18Dourish C, O'Neill M, Coughlan J, et al. (1990) The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur JPharmacol 176: 35.

19Simpson KH, Serpell M, McCubbins TD, et al. A multi-dose study: Management of neuropathic pain in patients using a CCK antagonist devazepide (DEVACADE®) as an adjunct to strong opioids. In World Congress of 10th IASP 2002; San Diego, CA, U.S.A

20Lattmann E, Russell ST, Schwalbe CH, et al. (2016) Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agent. Med Chem Commun 7: 1138.

21Lattmann E,Sattayasai J, Narayanan R, et al. (2017) Cholecystokinin-2/gastrin antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anti-inflammatory analgesics for the treatment of inflammatory bowel disease. Med Chem Commun 8: 680.

22Baber S, Dourish T, HillR (1989) The role of CCK caerulein, and CCK antagonists in nociception. Pain 39: 307.

23Saita Y, Yazawa H, Honma, Y, Nishida A, Miyata K et al. (1994) Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization. Eur J Pharmacol 269: 249-281.

24Charpentier B, Pelaprat D, Durieux C, Dor A, Reibaud M (1988) Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci.U.S.A 85:1968-1973.

25Lattmann E, Ayuko WO, Kinchinaton D, et al. (2003) Synthesis and evaluation of 5-arylated 2(5H)-furanones and 2-arylated pyridazin-3(2H)-ones as anticancer agents. J Pharm Pharm 55: 1259. 37: 722.

26Lattmann E, Boonprakob Y, Sattayasai J (2008) Part 2. Long term in vivo/in vitro evaluation of the Cholecystokinin antagonists: N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylurea MPP and carboxamide MPM. Drug DiscovTher 2: 344.

27Revel L, Mennuni L, Garofalo P, et al. (1998) CR 2945: A novel CCKB receptor antagonist with anxiolytic like activity. BehavPharmacol 9: 183.

28Sramek JJ, Kramer MS, Reines SA, et al. (1994) Pilot study of a CCKB antagonist in patients with panic disorder: Preliminary findings.Anxiety 1: 141.

29Lattmann E, Sattayasai J, Schwalbe CH, Boonprakob Y, Dunn S(2016) Analgesic Effects of 5-Alkyloxy-4-amino-2(5H)-furanones as Cholecystokinin-2 Antagonists. Arch Pharm (Weinheim) 349: 456-65.

30Hussain MSH, York P, Timmins P (1992) Effect of commercial and high purity magnesium stearates on in-vitro dissolution of paracetamol DC tablets. International journal of pharmaceutics 78: 203-207.

31Zhang Y, Law Y, Chakrabarti S (2003) Physical properties and compact analysis of commonly used direct compression binders. AAPSPharmscitech 4: 489-499.

32Missaghi S, Fassihi R (2006) Evaluation and comparison of physicomechanical characteristics of gelatin and hypromellose capsules. Drug development and industrial pharmacy 32: 829-838.

33Aulton ME, Taylor KM (2013) Aulton's Pharmaceutics: the design and manufacture of medicines. 4th ed. London: Churchill Livingstone Elsevier.

34Qiu S, Wang K, Li M (2014) In vitro dissolution studies of immediate-release and extended-release formulations using flowthrough cell Apparatus 4. Dissolution Technologies 21: 6-16.

35Bushra R, Shoaib MH, Aslam N, Hashmat D, Rehman M (2008)Formulation development and optimization of ibuprofen tablets by direct compression method. Pak. J. Pharm. Sci 21: 113-120.

36Zhao N, Augsburger LL (2005) Functionality comparison of 3 classes of superdisintegrants in promoting aspirin tablet disintegration and dissolution. AAPS Pharmscitech 6: E634-E640.

37D'Amato M, Stamford IF, Bennett (1991) A Studies of three nonpeptide cholecysto-kinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pigileum. Br JPharmacol 102: 391.

38Bradwejn J, Koszycki D, Couetoux du Tertre A, et al. (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiat 51: 486.

39D'Amato M, Stamford I, Bennett A (1990) The effects of cholecystokinin octa-peptide on human isolated alimentary muscle. BrJPharmacol 100: 126.

40Kenakin T, JenkinsonS, Watson C (2006) Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists. J Pharmacol Exp Ther 319: 710.

41Schultheiss G, Diener M (1999) Inhibition of spontaneous smooth muscle contractions in rat and rabbit intestine. Journal of Veterinary Medicine.